Japan approves dexamethasone as coronavirus treatment


  • World
  • Wednesday, 22 Jul 2020

TOKYO (Reuters) - Japan's health ministry has approved dexamethasone, a cheap and widely used steroid, as a second treatment of COVID-19 after a trial in Britain showed the drug reduced death rates in hospitalised patients.

The ministry included dexamethasone as an option for treatment along with antiviral drug remdesivir in a recent revision to its handbook. The revision was widely reported by Japanese media on Wednesday.

In results announced last month, a trial by researchers in the United Kingdom showed dexamethasone as the first drug to save lives of COVID-19 patients in what scientists said was a major breakthrough in the coronavirus pandemic.

Japan's Nichi-Iko Pharmaceutical Co is among those that produce the drug.

(Reporting by Chang-Ran Kim; Editing by Jacqueline Wong)

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 3
   

Did you find this article insightful?

Yes
No

Next In World

Myanmar's U.N. ambassador vows to fight after junta fired him
Ten arrested in Barcelona as protests over jailed rapper turn violent
Biden says he will make announcement on Saudi Arabia on Monday
France reports 23,996 new COVID-19 cases, 186 deaths
Cuba approves animal welfare law after civil society pressure
Italy reports 280 coronavirus deaths on Saturday, 18,916 new cases
As Mexico's largest migrant camp empties, new tents spring up along border
Spanish government says all cattle on pariah ship should be killed
Analysis: U.S. seeks to put Saudi crown prince in his place - for now
Russian scientists say Sputnik V performs well against COVID mutations

Stories You'll Enjoy


Vouchers